

Date: 31st October, 2026

To,
Corporate Relations Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
Company Code: ACCPL

Dear Sir/ Madam,

Subject: Outcome of the Board Meeting dated 31st October, 2026
Reference: Disclosure pursuant to Regulations 30 read with Regulation 33 of the SEBI
(Listing Obligations and Disclosure Requirements) Regulations, 2015.

With reference to the captioned subject, we wish to inform you that the Board of Directors of the Company at its meeting held today i.e. 31st October, 2026 has, inter-alia considered and approved Unaudited Financial Results for the half-year ended 30th September, 2026 along with Limited Review Reports of the Statutory Auditors thereon. The said Financial Results are enclosed herewith and will be available at Company's website www.accretionpharma.com.

The Board Meeting commenced at 12:00 noon and concluded at 12.40 p.m.

You are requested to kindly take on your record.

Thanking You.

Yours truly,
For Accretion Pharmaceuticals Limited

ROSHNI
DHARMENDRABHAI
SHAH

Digitally signed by ROSHNI
DHARMENDRABHAI SHAH
Date: 2026.10.31 12:49:51
+05'30'

Roshni Shah
Company Secretary and Compliance Officer

Encl: as above

Limited Review Report


To,
Board of Directors
ACCRETION PHARMACEUTICALS LIMITED
29 Xcelon Ind Park 1,
B/h, Intas Pharmaceuticals,
Vasna Chacharvadi,
Ahmedabad,
Sanand -382213.

1. We have reviewed the accompanying statement of unaudited financial results of **ACCRETION PHARMACEUTICALS LIMITED** (CIN: L21004GJ2023PLC146545) for the half year ended 30th September, 2026 which are included in the accompanying "Statement of Unaudited Financial Result for half year ended September 30, 2026" together with relevant notes thereon. The statement has been prepared by company pursuant to regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The statement is the responsibility of the company's management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the AS 25 "Interim Financial Reporting (AS 25)", prescribed under section 133 of the companies act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the ICAI. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review of Interim Financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an Audit. Accordingly, we do not express an Audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with the recognition and measurement principles laid down in the aforesaid Accounting Standards ('AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Date : 31/10/2026
Place : Ahmedabad



For, **V S S B & Associates**
Chartered Accountants.
Firm No. 121356W



(Vishves A. Shah)
Partner

M. No. 109944

UDIN:26109944YLVCEYE1446

ACCRETION PHARMACEUTICALS LIMITED

(CIN: L21004GJ2023PLC146545)

Regd. Office :- 29 Xcelon Ind Park I, B/h, Intas Pharmaceuticals, Vasna Chacharvadi, Ahmedabad, Sanand, Gujarat, India, 382213

Corporate Office:- 516, Iconic Shyamal, Shyamal Cross Road, 132 Feet Ring Road, Satellite, Azad Society, Ahmedabad, Ahmedabad City, Gujarat, India, 380015

Unaudited Statement of Standalone Financial Result for the half year /year ended September 30, 2026

(Amount in Lakhs)

	Particulars	Half Year Ended			Year Ended
		30-09-26	30-09-25	31-03-26	31-03-26
		(Unaudited)	(Unaudited)	(Audited)	(Audited)
I	Revenue from Operations	5504.10	4373.62	4589.09	8962.71
II	Other Income	14.54	11.05	8.00	19.05
III	Total Income (I + II)	5518.64	4384.67	4597.10	8981.76
IV	Expenses				
	Cost of Material Consumed	3756.54	3439.68	3501.95	6941.63
	Purchases	0.00	0.00	0.00	0.00
	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(5.70)	(224.25)	(202.10)	(426.34)
	Employee Benefits Expenses	226.31	205.67	242.90	448.57
	Finance Costs	65.33	37.07	47.71	84.79
	Depreciation and Amortization Expense	87.45	39.97	81.14	121.11
	Other Expenses	304.22	245.45	258.25	503.71
	Total Expense	4434.15	3743.59	3929.86	7673.45
V	Profit before Exceptional and Extraordinary Items and Tax (III-IV)	1084.49	641.07	667.24	1308.31
VI	Exceptional Items	0.00	0.00	0.00	0.00
VII	Profit before Extraordinary Items and Tax (V-VI)	1084.49	641.07	667.24	1308.31
VIII	Extraordinary Items	0.00	0.00	0.00	0.00
IX	Profit Before Tax (VII-VIII)	1084.49	641.07	667.24	1308.31
X	Tax Expense:				
	(a) Current Tax	263.00	161.35	174.38	335.72
	(b) Deferred Tax	0.10	4.51	3.28	7.78
	(c) MAT Credit Entitlement	0.00	0.00	0.00	0.00
	(d) Income Tax of Previous Year	1.25	0.00	(1.94)	(1.94)
	Total Tax Expense	264.35	165.85	175.71	341.56
XI	Profit for the Period from Continuing Operations (IX - X)	820.14	475.22	491.53	966.75
XII	Profit/(Loss) for the Period from Discontinuing Operations	0.00	0.00	0.00	0.00
XIII	Tax Expense of Discontinuing Operations	0.00	0.00	0.00	0.00
XIV	Profit/(Loss) from Discontinuing Operations (After Tax) (XII-XIII)	0.00	0.00	0.00	0.00
XV	Profit for the Period (XI + XIV)	820.14	475.22	491.53	966.75
XVI	Paid up Share Capital (Face Value Rs. 10/Share)	1111.60	1111.60	1111.60	1111.60
XVII	Reserve excluding Revaluation Reserves				4359.25
XVIII	Earnings Per Equity Share:				
	Basic (Rs.) & Diluted	7.38	4.61	4.42	9.03

Notes:

- The above Un-audited financial results were reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 31st October 2026.
- The previous periods figures have been regrouped wherever necessary.
- The Company is mainly engaged in the business of manufacture, process, trade, sale, purchase, import, export, assemble, distribute, formulate, develop, consult, test and deal in all kind of Drugs, Pharmaceuticals products and related products thereto and which is considered as only reportable primary business segment as per Accounting Standard "Segment Reporting" (AS - 17). As such, no separate disclosure for Segment Reporting is made.
- During the Preceding Previous year, the company had made an initial public offering (IPO) of 29,46,000 equity shares of face value of Rs. 10 each fully paid up for cash at a price of Rs. 101 per equity shares (including share premium of Rs. 91 per equity share) aggregating to Rs. 29,75,46,000/- The equity shares of the company got listed on NSE Emerge Platform on 21st May, 2025.
- The funds raised through the Initial Public Offer (IPO) had been fully utilised as at 31 March 2026. Accordingly, no further utilisation of IPO proceeds was pending as at 30 September 2026.

Place: Ahmedabad
Date : 31/10/2026



**For and on Behalf of the Board of,
ACCRETION PHARMACEUTICALS LIMITED**

Vivek Ashok Kumar Patel
(Managing Director)
DIN : 09130357

ACCRETION PHARMACEUTICALS LIMITED

(CIN: L21004GJ2023PLC146545)

Regd. Office :- 29 Xcelon Ind Park 1, B/h, Intas Pharmaceuticals, Vasna Chacharvadi, Ahmedabad, Sanand, Gujarat, India, 382213

Corporate Office:- 516, Iconic Shyamal, Shyamal Cross Road, 132 Feet Ring Road, Satellite, Azad Society, Ahmedabad, Ahmedabad City, Gujarat, India, 380015


Unaudited Statement of Assets & Liabilities as at 30th September, 2026

(Amount in Lakhs)

	Particulars	Unaudited AS AT 30-09-2026	Audited AS AT 31-03-2026
I	Equity & Liabilities		
	1. Shareholders' funds		
	(a) Share Capital	1111.60	1111.60
	(b) Reserves and Surplus	5179.40	4359.25
	(c) Money received against share warrants	0.00	0.00
	2. Share application money pending allotment	0.00	0.00
	Total	6291.00	5470.85
	3. Non - Current Liabilities		
	(a) Long -Term Borrowings	528.93	86.25
	(b) Deferred Tax Liabilities (Net)	27.34	27.24
	(c) Other Long - Term Liabilities	0.00	0.00
	(d) Long - Term Provisions	0.00	0.00
	4. Current Liabilities		
	(a) Short - Term Borrowings	1144.77	1145.87
	(b) Trade Payables		
	Micro and Small Enterprises	92.69	158.87
	Other than Micro and Small Enterprises	368.26	417.70
	(c) Other Current Liabilities	9.25	5.35
	(d) Short - Term Provisions	273.41	353.42
	Total	2444.65	2194.70
	Total	8735.65	7665.55
II	Assets		
	1. Non - Current Assets		
	(a) Property, Plant & Equipment & Intangible Assets		
	(i) Property, Plant & Equipment	1340.67	1321.17
	(ii) Intangible Assets	0.00	0.00
	(iii) Capital Work-in-Progress	167.22	20.20
	(iv) Intangible Assets under Development	0.00	0.00
	(b) Non - Current Investments	0.00	0.00
	(c) Long - Term Loans and Advances	7.80	8.25
	(d) Other Non - Current Assets	224.89	256.62
	(e) Deferred Tax Assets (Net)	0.00	0.00
	Total	1740.57	1606.24
	2. Current Assets		
	(a) Inventories	2998.86	2837.46
	(b) Trade Receivables	3197.65	2240.01
	(c) Cash and Cash equivalents	212.67	402.06
	(d) Short - Term Loans and Advances	550.54	554.07
	(e) Other Current Assets	35.36	25.71
	Total	6995.08	6059.31
	Total	8735.65	7665.55

Place : Ahmedabad

Date : 31/10/2026



For & on behalf of the Board,
ACCRETION PHARMACEUTICALS LIMITED


Vivek Ashok Kumar Patel
(Managing Director)

DIN : 09130357

ACCRETION PHARMACEUTICALS LIMITED

(CIN: L21004GJ2023PLC146545)

Regd. Office :- 29 Xcelon Ind Park 1, B/h, Intas Pharmaceuticals, Vasna Chacharvadi, Ahmedabad, Sanand, Gujarat, India, 382213

Corporate Office:- 516, Iconic Shyamal, Shyamal Cross Road, 132 Feet Ring Road, Satellite, Azad Society, Ahmedabad, Ahmedabad City, Gujarat, India, 380015

UNAUDITED CASH FLOW STATEMENT FOR THE HALF YEAR ENDED 30th September 2026

Particulars	(Amount in Lakhs)	
	Period ended	Year ended
	30th September, 2026 (Unaudited) Rs.	31st March, 2026 (Audited) Rs.
CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit before Tax for the year	1,084.49	1,308.31
Adjustments for :		
Finance Cost	65.33	84.79
Depreciation	87.45	121.11
	152.78	205.89
Operating Profit before Working Capital change	1,237.27	1,514.20
Adjustments for :		
Decrease/(Increase) in Receivables	(957.64)	(776.49)
Decrease/(Increase) in Inventories	(161.40)	(1,073.90)
Decrease/(Increase) in Loans & Advances	3.54	(444.40)
Decrease/(Increase) in Other Current Assets	(9.65)	(13.52)
(Increase)/Decrease in Other Non Current Asset	31.74	(240.54)
Increase/(Decrease) in Trade Payables	(115.62)	(182.05)
Increase/(Decrease) in Current Liabilities	3.90	0.88
Increase/(Decrease) in Long Term Liabilities	-	-
Increase/(Decrease) in Provisions	(80.01)	87.52
	(1,285.15)	(2,642.50)
Cash Generated From Operations	(47.89)	(1,128.30)
Income Tax	264.25	333.78
NET CASH FROM OPERATING ACTIVITIES Total (A)	(312.14)	(1,462.08)
CASH FLOW FROM INVESTING ACTIVITIES		
Non Current Investment	-	-
Purchase Of Fixed Asset	(253.96)	(853.38)
Loans & Advances Given	0.45	-
NET CASH USED IN INVESTING ACTIVITIES Total (B)	(253.51)	(853.38)
CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from share issued (net off share issuing expense)	-	2,975.46
Net Repayment of Long Term Borrowing	-	(30.52)
Net Proceeds From Long Term Borrowing	442.68	-
Net Repayment of Short Term Borrowing	(1.09)	(147.72)
Interest Expenses	(65.33)	(84.79)
NET CASH FROM FINANCING ACTIVITIES Total (C)	376.26	2,712.44
Net Increase/(Decrease) in Cash and Cash Equivalents Total (A+B+C)	(189.38)	396.98
Cash and Cash Equivalents - Opening Balance	402.06	5.08
Cash and Cash Equivalents - Closing Balance	212.67	402.06
	(0.00)	-
Note: Previous year's figures have been regrouped/rearranged wherever considered necessary.		

For & on behalf of the Board,
ACCRETION PHARMACEUTICALS LIMITED



[Signature]

Vivek Ashok Kumar Patel
(Managing Director)
DIN : 09130357

Place : Ahmedabad
Date : 31/10/2026